Eledon CEO

Eledon's CEO, Dr. David-Alexandre Gros, breaks down Tegoprubart, the company’s targeted immunosuppressant being studied alongside islet cell transplants for type 1 diabetes. The conversation covers the promising results seen so far, including insulin independence and improved A1C levels among trial participants, and why Tego could offer a different approach to protecting transplanted cells. The episode also explores what the future of type 1 diabetes treatment could look like as transplantation, stem-cell-derived islets, and new immunosuppressive therapies continue to advance.   Learn about the Eversense 365 CGM   Learn about Omnipod 5 (sponsor)*   Watch Next: Type 1 Diabetes Cure Research    Join: Diabetech Newsletter (free) | Diabetech All Access   Follow Diabetech: Instagram | Tik Tok | YouTube | Facebook | Discord   DISCLAIMER: This podcast is not medical advice and is for educational purposes only. Always consult with your doctor before making changes to your health care.    *10-day trial eligibility may vary. Full terms and conditions apply. Visit omnipod.com/diabetech for clinical disclaimers, terms and important safety information. The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.